Nu-3 showed consistent in vitro activity against MRSA, MSSA, VRE, and VSE from recent diabetic foot ulcer isolates. MIC values were 2–8 times lower than planned doses. Phase 2a topline data expected Q1 2027.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
